DUBLIN--(BUSINESS WIRE)--Sep 11, 2018--The "Global Primary Sclerosing Cholangitis Treatment Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.

The Global Primary Sclerosing Cholangitis Treatment Market to grow at a CAGR of 3.57% during the period 2018-2022.

Global Primary Sclerosing Cholangitis Treatment market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

According to the report, one driver influencing this market is the rise in number of liver transplants and UDCA treatment. Chronic liver diseases are a major reason for increasing mortality rates. The increasing rate of mortality due to liver disease is expected to fuel the growth of PSC treatment market.

One trend affecting this market is the development of affordable PSC drugs. Several companies are coming up with new therapeutic candidates for the treatment of the disease.

Further, the report states that one challenge affecting this market is the poor understanding of PSG pathogenesis. Chronic inflammatory diseases, such as PSC, may lead to cancer and the pathogenesis and molecular mechanisms of cholangiocarcinoma is not well known.

Market trends

Development of affordable PSC drugs Surrogate endpoints for clinical trials in PSC siRNA therapeutic products for treatment of PSC

Key vendors

Allergan Glenmark Impax Laboratories Mylan Teva Pharmaceuticals

Key Topics Covered:

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Market Sizing

Part 06: Five Forces Analysis

Part 07: Pipeline Landscape

Part 08: Market Segmentation By Product

Part 09: Customer Landscape

Part 10: Regional Landscape

Part 11: Decision Framework

Part 12: Drivers And Challenges

Part 13: Market Trends

Part 14: Vendor Landscape

Part 15: Vendor Analysis

For more information about this report visit https://www.researchandmarkets.com/research/d4rxk7/global_primary?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180911005668/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Liver and Kidney Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/11/2018 01:15 PM/DISC: 09/11/2018 01:15 PM

http://www.businesswire.com/news/home/20180911005668/en